Conzip is a drug owned by Cipher Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 11, 2022. Details of Conzip's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7858118 | Extended release composition containing Tramadol |
Apr, 2022
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Conzip's patents.
Latest Legal Activities on Conzip's Patents
Given below is the list of recent legal activities going on the following patents of Conzip.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 Dec, 2021 | US7858118 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 04 Jan, 2018 | US7858118 |
| Recordation of Patent Grant Mailed Critical | 28 Dec, 2010 | US7858118 |
| Patent Issue Date Used in PTA Calculation Critical | 28 Dec, 2010 | US7858118 |
| Issue Notification Mailed Critical | 08 Dec, 2010 | US7858118 |
| Application Is Considered Ready for Issue Critical | 23 Nov, 2010 | US7858118 |
| Dispatch to FDC | 23 Nov, 2010 | US7858118 |
| Issue Fee Payment Verified Critical | 12 Nov, 2010 | US7858118 |
| Issue Fee Payment Received Critical | 12 Nov, 2010 | US7858118 |
| Mail Notice of Allowance Critical | 01 Oct, 2010 | US7858118 |
US patents provide insights into the exclusivity only within the United States, but Conzip is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Conzip's family patents as well as insights into ongoing legal events on those patents.
Conzip's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Conzip's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 11, 2022 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Conzip Generic API suppliers:
Tramadol Hydrochloride is the generic name for the brand Conzip. 28 different companies have already filed for the generic of Conzip, with Sun Pharm having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Conzip's generic
Alternative Brands for Conzip
Conzip which is used for managing moderate to moderately severe chronic pain., has several other brand drugs using the same active ingredient (Tramadol Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Athena |
| |
| Janssen Pharms |
| |
| Kowa Pharms |
| |
| Purdue Pharma |
| |
| Shionogi Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Tramadol Hydrochloride, Conzip's active ingredient. Check the complete list of approved generic manufacturers for Conzip
About Conzip
Conzip is a drug owned by Cipher Pharmaceuticals Inc. It is used for managing moderate to moderately severe chronic pain. Conzip uses Tramadol Hydrochloride as an active ingredient. Conzip was launched by Cipher Pharms Inc in 2010.
Approval Date:
Conzip was approved by FDA for market use on 07 May, 2010.
Active Ingredient:
Conzip uses Tramadol Hydrochloride as the active ingredient. Check out other Drugs and Companies using Tramadol Hydrochloride ingredient
Treatment:
Conzip is used for managing moderate to moderately severe chronic pain.
Dosage:
Conzip is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 200MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 300MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |